Journal
AMERICAN HEART JOURNAL
Volume 165, Issue 4, Pages 489-500Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2013.01.011
Keywords
-
Categories
Ask authors/readers for more resources
Recent advances in electrocardiographic monitoring and waveform analysis have significantly improved the ability to detect drug-induced changes in cardiac repolarization manifested as changes in the QT/corrected QT interval. These advances have also improved the ability to detect drug-induced changes in cardiac conduction. This White Paper summarizes current opinion, reached by consensus among experts at the Cardiac Safety Research Consortium, on the assessment of electrocardiogram-based safety measurements of the PR and QRS intervals, representing atrioventricular and ventricular conduction, respectively, during drug development. (Am Heart J 2013;165:489-500.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available